摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-hydroxy-5-(pyridin-3-yl)benzoic acid | 23380-76-9

中文名称
——
中文别名
——
英文名称
2-hydroxy-5-(pyridin-3-yl)benzoic acid
英文别名
5-(3-Pyridyl)salicylsaeure;5-(pyridin-3-yl)salicylic acid;2-hydroxy-5-pyridin-3-ylbenzoic acid
2-hydroxy-5-(pyridin-3-yl)benzoic acid化学式
CAS
23380-76-9
化学式
C12H9NO3
mdl
——
分子量
215.208
InChiKey
GJSFZMHGFSKOAK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    70.4
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-hydroxy-5-(pyridin-3-yl)benzoic acidN,N-二甲基甲酰胺 吡啶草酰氯 作用下, 以 二氯甲烷 为溶剂, 反应 6.5h, 生成 methyl 2-(2-acetoxy-5-(pyridin-3-yl)benzamido)-4-(furan-2-yl)benzoate
    参考文献:
    名称:
    N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF
    摘要:
    通用公式(1)表示的N-酰基蒽酸衍生物或其盐对预防或治疗与胶原蛋白过度产生相关的疾病具有用处。(在该公式中,R1代表羧基或类似物;R2代表氢原子或类似物;R3代表可选择取代的芳基或类似物;X1代表羰基;X2代表连接手;X3代表连接手;X4代表连接手或类似物;A代表可选择取代的苯基或类似物。)
    公开号:
    US20110275797A1
  • 作为产物:
    描述:
    ethyl 2-hydroxy-5-(pyridin-3-yl)benzoate 在 lithium hydroxide monohydrate 作用下, 反应 12.0h, 以99%的产率得到2-hydroxy-5-(pyridin-3-yl)benzoic acid
    参考文献:
    名称:
    Bi-aryl Analogues of Salicylic Acids: Design, Synthesis and SAR Study to Ameliorate Endoplasmic Reticulum Stress
    摘要:
    Introduction: Endoplasmic reticulum (ER) stress condition is characterized as the accumulation of misfolded or unfolded proteins in lumen of ER. This condition has been implicated in various diseases and pathologies including β-cell apoptosis, Alzheimer's disease and atherosclerosis. We have reported that hydroxynaphthoic acids (HNA), naphthalene analogues of salicylic acid (SA), reduced ER stress. In this study, we explored structural modification to bi-aryl analogues of SA. Methods: Palladium-catalyzed cross-coupling was applied to synthesize bi-aryl analogues of SA. Anti-ER stress activity was monitored by using our cell-based assay system where ER stress is induced by tunicamycin. To monitor ER stress markers, ER stress was induced physiologically relevant palmitate system. Results: Many analogues decreased ER stress signal induced by tunicamycin. Compounds creating dihedral angle between Ar group and SA moiety generally increased the activity but gave some cytotoxicity to indicate the crucial role of flat conformation of aromatic region. The best compound (16e) showed up to almost 6-fold and 90-fold better activity than 3-HNA and tauro-ursodeoxycholic acid, positive controls, respectively. ER stress markers such as p-PERK and p-JNK were accordingly decreased in Western blotting upon treatment of 16e under palmitate-induced condition. Conclusion: Anti-ER stress activity and toxicity profile of bi-aryl analogues of SA could provide a novel platform for potential therapy for protein misfolding diseases.
    DOI:
    10.2147/dddt.s319287
点击查看最新优质反应信息

文献信息

  • Structural Modifications of Salicylates: Inhibitors of Human CD81‐Receptor HCV‐E2 Interaction
    作者:Marcel Holzer、Sigrid Ziegler、Alexander Neugebauer、Bernd Kronenberger、Christian D. Klein、Rolf W. Hartmann
    DOI:10.1002/ardp.200700261
    日期:2008.8
    extracellular loop (LEL) of the CD81receptor (crystal structure: PDB‐ID: 1G8Q). After benzyl salicylate had been experimentally validated to be a moderate inhibitor of the CD81‐LEL–HCV‐E2 interaction, further optimization was performed and heterocyclic‐substituted benzyl salicylate derivatives were synthesized. The compounds were tested for their ability to inhibit the interaction of a fluorescence‐labeled
    本文的出发点是使用 CD81 受体(晶体结构:PDB-ID:1G8Q)的大细胞外环(LEL)的开放构象进行虚拟筛选的结果。在实验证实水杨酸苄酯是 CD81-LEL-HCV-E2 相互作用的温和抑制剂后,进行了进一步优化并合成了杂环取代的水杨酸苄酯衍生物。使用 HUH7.5 细胞测试了这些化合物抑制荧光标记抗体与 CD81-LEL 相互作用的能力。与水杨酸苄酯相比,没有化合物显示出抑制蛋白质-蛋白质相互作用的增加。
  • N-acyl anthranilic acid derivative or salt thereof
    申请人:Yokotani Junichi
    公开号:US08492582B2
    公开(公告)日:2013-07-23
    The invention relates to an N-acyl anthranilic acid derivative or it's salt having collagen production inhibitory action.
    本发明涉及一种具有胶原蛋白生成抑制作用的N-酰基蒽酰氨酸衍生物或其盐。
  • SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway
    作者:Hee-Don Chae、Nick Cox、Samanta Capolicchio、Jae Wook Lee、Naoki Horikoshi、Sharon Kam、Andrew A. Ng、Jeffrey Edwards、Tae-León Butler、Justin Chan、Yvonne Lee、Garrett Potter、Mark C. Capece、Corey W. Liu、Soichi Wakatsuki、Mark Smith、Kathleen M. Sakamoto
    DOI:10.1016/j.bmcl.2019.06.023
    日期:2019.8
    Disruption of cyclic adenosine monophosphate response element binding protein (CREB) provides a potential new strategy to address acute leukemia, a disease associated with poor prognosis, and for which conventional treatment options often carry a significant risk of morbidity and mortality. We describe the structure-activity relationships (SAR) for a series of XX-650-23 derived from naphthol AS-E phosphate that disrupts binding and activation of CREB by the CREB-binding protein (CBP). Through the development of this series, we identified several salicylamides that are potent inhibitors of acute leukemia cell viability through inhibition of CREB-CBP interaction. Among them, a biphenyl salicylamide, compound 71, was identified as a potent inhibitor of CREB-CBP interaction with improved physicochemical properties relative to previously described derivatives of naphthol AS-E phosphate.
  • US8492582B2
    申请人:——
    公开号:US8492582B2
    公开(公告)日:2013-07-23
  • N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF
    申请人:Yokotani Junichi
    公开号:US20110275797A1
    公开(公告)日:2011-11-10
    An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R 1 represents a carboxyl group or the like; R 2 represents a hydrogen atom or the like; R 3 represents an optionally substituted aryl group or the like; X 1 represents a carbonyl group; X 2 represents a bonding hand; X 3 represents a bonding hand; X 4 represents a bonding hand or the like; and A represents an optionally substituted phenyl group or the like.)
    通用公式(1)表示的N-酰基蒽酸衍生物或其盐对预防或治疗与胶原蛋白过度产生相关的疾病具有用处。(在该公式中,R1代表羧基或类似物;R2代表氢原子或类似物;R3代表可选择取代的芳基或类似物;X1代表羰基;X2代表连接手;X3代表连接手;X4代表连接手或类似物;A代表可选择取代的苯基或类似物。)
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-